Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review

Journal of Controlled Release

Volumn 65, Issue 1-2, 2000, Pages 271-284

  Maeda, H ^a   Wu, J ^a   Sawa, T ^a   Matsumura, Y ^b   Hori, K ^c  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY   (Japan)

Author keywords

EPR effect; Macromolecular therapeutics; Permeability factors; Tumor targeting; Tumor vascular permeability

Indexed keywords

ANTINEOPLASTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ICATIBANT; LIPID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; OVOMUCOID; PEROXYNITRITE; POLYMER; VASCULOTROPIN; ZINOSTATIN MALEIC ACID STYRENE COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TISSUE LEVEL; HYPERTENSION; MACROMOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TUMOR GROWTH; TUMOR VASCULARIZATION;

EID: 0034000453     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00248-5     Document Type: Article

References (55)

1. Matsumura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46:1986;6387-6392.
2. Maeda H., Matsumura Y. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6:1989;193-210.
3. Muggia F. Doxorubicin-polymer conjugates: Further demonstration of the concept of enhanced permeability and retention. Clin. Cancer Res. 5:1999;7-8.
4. Maeda H. SMANCS and polymer-conjugated macromolecular drugs: Advantages in cancer chemotherapy. Adv. Drug Delivery Rev. 6:1991;181-202.
5. Vasey P.A., Kaye S.B., Morrison R., Tweleves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
6. Maeda H., Seymour L.W., Miyamoto Y. Conjugation of anticancer agents and polymers: Advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;357-362.
7. Iwai K., Maeda H., Konno T. Use of oily contrast medium for selective drug targeting to tumor: Enhanced therapeutic effect and X-ray image. Cancer Res. 44:1984;2115-2121.
8. Iwai K., Maeda H., Konno T., Matsumura Y., Yamashita R., Yamasaki K., Hirayama S., Miyauchi Y. Tumor targeting by arterial administration of lipids: Rabbit model with VX2 carcinoma in the liver. Anticancer Res. 7:1987;321-328.
9. 3] bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263:1988;16051-16054.
10. Matsumura Y., Kimura M., Yamamoto T., Maeda H. Involvement of the kinin-generating cascade and enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79:1988;1327-1334.
11. Maeda H., Noguchi Y., Sato K., Akaike T. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85:1994;331-334.
12. Doi K., Akaike T., Horie H., Noguchi Y., Fujii S., Beppu T., Ogawa M., Maeda H. Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer. 77:1996;1598-1604.
13. Wu J., Akaike T., Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58:1998;159-165.
14. J. Wu, T. Sawa, T. Akaike, H. Maeda, Peroxynitrite and oxygen radical species: Roles in EPR effect and the implication for solid tumor therapy, (Abstract) 3rd Intl. Symp. on Polymer Therapeutics, January 7-9, London, UK, 1998.
15. Senger D.R., Galli S.J., Dvorak A.M., Perruzzi C.A., Harvey V.S., Dvorak H.F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science. 219:1983;983-985.
16. Leung D.W., Cachianes G., Kuang W.J., Goeddel D.V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1989;1306-1309.
17. Papapetropoulos A., Garcia-Cardena G., Madri J.A., Sessa W.C. Nitric oxide production contributes to the angiogenic properties of vascular endothelial growth factor in human endothelial cells. J. Clin. Invest. 100:1997;3131-3139.
18. H. Maeda, J. Wu, T. Okamoto, K. Maruo, T. Akaike, Kallikrein-kinin in infection and cancer, Immunopharmacology 12 (1999).
19. Maeda H. Role of microbial proteases in pathogenesis (Review). Microbiol. Immunol. 40:1996;685-699.
20. Peterson H.I., Apergren K.L. Experimental studies on the uptake and retention of labelled proteins in a rat tumor. Eur. J. Cancer. 9:1973;543-547.
21. Molla A., Yamamoto T., Akaike T., Miyoshi S., Maeda H. Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 264:1989;10589-10594.
22. Noguchi Y., Wu J., Duncan R., Strohalm J., Ulbrich K., Akaike T., Maeda H. Early phase tumor accumulation of macromolecules: A great difference between the tumor vs. normal tissue in their clearance rate. Jpn. J. Cancer Res. 89:1998;307-314.
23. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., Duncan R. Tumour tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in subcutaneous murine B16F10 melanoma. Br. J. Cancer. 70:1997;636-641.
24. Duncan R., Sat Y.-N. Tumor targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol. 9:(2):1998;39.
25. Takakura Y., Hashida M. Macromolecular carrier systems for targeting drug delivery: Pharmacokinetic considerations on biodistribution. Pharm. Res. 13:1996;820-831.
26. Maeda H., Takeshita J., Kanamaru R., Sato H., Katoh J. Antimetastatic and antitumor activity of a derivative of neocarzinostatin: An organic solvent- and water-soluble polymer-conjugated protein. Gann. 70:1979;601-606.
27. Takeshita J., Maeda H., Kanamaru R. In vitro mode of action, pharmacokinetics, and organ specificity of poly(maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Gann. 73:1982;278-284.
28. Maeda H., Matsumoto T., Konno T., Iwai K., Ueda M. Tailor-making of protein drugs by polymer conjugation for tumor targeting: A brief review on SMANCS. J. Protein Chem. 3:1984;181-193.
29. F.C. Curtice, The origin of lipoprotein in lymph, in: H.S. Meyersen (Chairman), Lymph and the Lymphatic System, Charles C. Thomas, Springfield, IL, 1963, pp. 89-126.
30. Maeda H., Matsumura Y. Cancer selective macromolecular therapeusis: Tailoring of an antitumor protein drug. Feeney R.E., Whitaker J.R. Protein Tailoring for Food and Medical Uses. 1985;353-382 Marcel Dekker, New York.
31. Kojima Y., Haruta A., Imai T., Otagiri M., Maeda H. Conjugation of Cu,Zn-superoxide dismutase with succinylated gelatin: Pharmacological activity and cell-lubricating function. Bioconjugate Chem. 4:1993;490-498.
32. 2: Improved stability of SOD in vitro and in vivo. J. Bioactive Compat. Polymers. 11:1996;169-190.
33. Konno T., Maeda H., Iwai K., Tashiro S., Maki S., Morinaga T., Mochinaga M., Hiraoka T., Yokoyama I. Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: A preliminary report. Eur. J. Cancer Clin. Oncol. 19:1983;1053-1065.
34. Konno T., Maeda H., Iwai K., Maki S., Tashiro S., Uchida M., Miyauchi Y. Selective targeting of anti-cancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer. 54:1984;2367-2374.
35. Maki S., Konno T., Maeda H. Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer. 56:1985;751-757.
36. Seymour L.W., Olliff S.P., Poole C.J., De Takats P.G., Orme R., Ferry D.R., Maeda H., Kerr D.J. A novel dosage approach for evaluation of SMANCS in the treatment of primary hepatocellular carcinoma. Int. J. Oncol. 12:1998;1217-1223.
37. Matsumoto K., Yamamoto T., Kamata R., Maeda H. Pathogenesis of serratial infection: Activation of the Hageman factor-prekallikrein cascade by serratial protease. J. Biochem. 96:1984;739-749.
38. Molla A., Matsumura Y., Yamamtoto T., Okamura R., Maeda H. Pathogenetic capacity of proteases from Serratia marcescens and Pseudomonas aeruginosa and their suppression by chicken egg white ovomacroglobulin. Infect. Immun. 55:1987;2509-2517.
39. Matsumura Y., Maruo K., Kimura M., Yamamoto T., Konno T., Maeda H. Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82:1991;732-741.
40. Akaike T., Noguchi Y., Ijiri S., Setoguchi K., Suga M., Zheng Y.M., Dietzschold B., Maeda H. Pathogenesis of influenza virus-induced pneumonia: Involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. USA. 93:1996;2448-2453.
41. Akaike T., Suga M., Maeda H. Free radicals in viral pathogenesis: Molecular mechanisms involving superoxide and NO. Proc. Soc. Exp. Biol. Med. 217:1998;64-73.
42. Umezawa K., Akaike T., Fujii S., Suga M., Setoguchi K., Ozawa A., Maeda H. Induction of nitric oxide synthesis and xanthine oxidase and their role in the antimicrobial mechanism against Salmonella typhimurium in mice. Infect. Immun. 65:1997;2932-2940.
43. Doi K., Akaike T., Fujii S., Tanaka S., Ikebe N., Beppu T., Setoguchi K., Takeya M., Shibahara S., Ogawa M., Maeda H. Induction of haeme oxygenase-1 by nitric oxide and ischemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer. 80:1999;1945-1954.
44. Okamoto T., Akaike T., Nagano T., Miyajima S., Suga M., Ando M., Ichimori K., Maeda H. Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: A novel mechanism for procollagenase activation involving nitric oxide. Arch. Biochem. Biophys. 342:1997;261-274.
45. Utoguchi N., Mizuguchi H., Dantakean A., Makimoto H., Wakai Y., Tsutsumi Y., Nakagawa S., Mayumi T. Effect of tumor cell-conditioned medium on endothelial macromolecular permeability and its correlation with collagen. Br. J. Cancer. 73:1996;24-28.
46. Lijnen H.R., Ugwu F., Bini A., Collen D. Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry. 14:1998;4699-4702.
47. Dvorak H.F., Brown L.F., Detmar M., Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. J. Natl. Cancer Inst. 146:1996;1029-1039.
48. Sakata Y., Akaike T., Suga M., Ijiri S., Ando M., Maeda H. Bradykinin generation triggered by Pseudomonas proteases facilitates invasion of the systemic circulation by Pseudomonas aeruginosa. Microbiol. Immunol. 40:1996;415-423.
49. Maruo K., Akaike T., Ono T., Maeda H. Involvement of bradykinin in intravascular dissemination of Vibrio vulnificus and prevention of invasion by a bradykinin antagonist. Infect. Immun. 66:1998;866-869.
50. Suzuki M., Hori K., Abe I., Saito H., Sato H. A new approach to cancer chemotherapy: Selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67:1981;663-669.
51. Li C.J., Miyamoto Y., Kojima Y., Maeda H. Augmentation of tumor delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cancer. 67:1993;975-980.
52. K. Hori, S. Saito, H. Takahashi, H. Sato, H. Maeda, Y. Sato, Tumor selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride, Jpn. J. Cancer Res. (2000), in press.
53. Zimmon D.S., Oratz M., Kessler R., Schreiber S.S., Rothschild M.A. Albumin to ascites: Demonstration of a direct pathway bypassing the systemic circulation. J. Clin. Invest. 48:1969;2074-2078.
54. Naito K., Kanbayashi N., Nakajima S., Murai T., Arakawa K., Nishimura S., Okuyama A. Inhibition of growth of human tumor cells in nude mice by a metalloprotease inhibitor. Int. J. Cancer. 58:1994;730-735.
55. Kennedy A.R. Chemopreventive agents: Protease inhibitors. Pharmacol. Ther. 78:1998;167-209.